Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy

Ray Y Hachem, Maha R Boktour, Hend A Hanna, Rola N Husni, Harrys A Torres, Claude Afif, Dimitrios P Kontoyiannis, Issam I Raad
2008-03-15
Abstract:BACKGROUND Invasive aspergillosis (IA) is a major cause of morbidity and mortality in patients with hematologic malignancy (HM). There are 2 lipid formulations of amphotericin B (AMB) currently in widespread use: AMB lipid complex (ABLC) and liposomal AMB (L‐AMB). There are limited data comparing the efficacy and safety of these 2 agents in the treatment of IA in patients with cancer. METHODS The authors retrospectively studied 381 consecutive patients with HM who had proven or probable IA (according to European Organization for Research and Treatment of Cancer/Mycosis Study Group of the National Institute of Allergy and Infectious Diseases criteria) between June 1993 and December 2005. Of these patients, 158 received primary antifungal therapy with either L‐AMB (n = 106) or ABLC (n = 52). The number of salvage antifungal regimens given were 51 L‐AMB regimens and 30 ABLC regimens …
What problem does this paper attempt to address?